Senesco Technologies will deliver an oral presentation titled ‘SNS01-T, an eIF5A-Based Gene Therapy Nanoparticle Designed for the Treatment of Multiple Myeloma, has Anti-Tumoral Activity in Lymphoma’ at the 15th Annual Meeting of the American Society of Gene & Cell Therapy.
The American Society of Gene & Cell Therapy conference will be conducted from May 16 to 19, 2012 at the Pennsylvania Convention Center located in Philadelphia, Pennsylvania. Catherine Taylor, who serves at the research laboratory of John Thompson, Chief Scientific Officer at Senesco Technologies, will discuss SNS01-T’s efficacy in B-cell cancers in the presentation during the Cancer-Targeted Gene & Cell Therapy Oral Abstract Session on May 17 2012. The laboratory is situated at the University of Waterloo in Ontario, Canada.
An incurable form of plasma cell cancer is multiple myeloma, wherein the accumulation of abnormal cells in the bone marrow affects the normal blood cell production and causes bone lesions. Plasma cells are white blood cells obtained from B-lymphocytes and produce antibodies.
Senesco Technologies’ key drug candidate to treat multiple myeloma is SNS01-T, which earned orphan drug status. SNS01-T carefully triggers apoptosis, a process of programmed cell death, by varying eukaryotic translation initiation factor 5A (eIF5A), which regulates cell growth and death. Apoptosis acceleration finds use in cancer treatment, while apoptosis delay finds use in the treatment of some ischemic and inflammatory diseases.
Source: http://www.senesco.com/